Advertisement

Surgery Today

, Volume 39, Issue 4, pp 290–294 | Cite as

Recent results of therapy for scirrhous gastric cancer

  • Masahide Ikeguchi
  • Takanori Miyake
  • Tomoyuki Matsunaga
  • Manabu Yamamoto
  • Youji Fukumoto
  • Yosinori Yamada
  • Kenji Fukuda
  • Hiroaki Saito
  • Shigeru Tatebe
  • Shun-ichi Tsujitani
Review Article

Abstract

The prognosis of patients with scirrhous gastric cancer (SGC) is extremely poor. However, recent advances in therapeutic strategies against SGC, using effective anticancer drugs, have prolonged the survival of patients with SGC. This paper reviews the recent therapeutic outcomes of this type of gastric cancer and introduces a new treatment protocol for SGC.

Key words

Intraperitoneal chemotherapy Laparoscopy Scirrhous gastric cancer 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kanter MA, Isaacson NH, Knoll AM, Nochomovitz LE. The diagnostic challenge of metastatic linitis plastica. Am Surg 1986; 52:510–513.PubMedGoogle Scholar
  2. 2.
    Takemura S, Yashiro M, Sunami T, Tendo M, Hirakawa K. Novel models for scirrhous gastric carcinoma in vivo. Cancer Sci 2004;95:893–900.PubMedCrossRefGoogle Scholar
  3. 3.
    Yanagihara K, Takigahira M, Tanaka H, Komatsu T, Fukumoto H, Koizumi F, et al. Development and biological analysis of peritoneal metastasis mouse model for human scirrhous stomach cancer. Cancer Sci 2005;96:323–332.PubMedCrossRefGoogle Scholar
  4. 4.
    Tanaka M, Kamata R, Takigahira M, Yanagihara K, Sakai R. Phosphorylation of ephrin-B1 regulates dissemination of gastric scirrhous carcinoma. Am J Pathol 2007;171:68–78.PubMedCrossRefGoogle Scholar
  5. 5.
    Powell DW. Myofibroblasts: paracrine cells important in health and disease. Trans Am Clin Climatol Assoc 2000;111:271–293.PubMedGoogle Scholar
  6. 6.
    Kano MR, Bae Y, Iwata C, Morishita Y, Yashiro M, Oka M, et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling. Proc Natl Acad Sci USA 2007;104:3460–3465.PubMedCrossRefGoogle Scholar
  7. 7.
    Qizilbash AH, Castelli M, Kowalski MA, Churly A. Endoscopic brush cytology and biopsy in the diagnosis of cancer of the upper gastrointestinal tract. Acta Cytol 1980;24:313–318.PubMedGoogle Scholar
  8. 8.
    Evans E, Harris O, Dickey D, Hartley L. Difficulties in the endoscopic diagnosis of gastric and oesophageal cancer. Aust NZ J Surg 1985;55:541–544.CrossRefGoogle Scholar
  9. 9.
    Levine MS, Kong V, Rubesin SE, Laufer I, Herlinger H. Scirrhous carcinoma of the stomach: radiologic and endoscopic diagnosis. Radiology 1990;175:151–154.PubMedGoogle Scholar
  10. 10.
    Park MS, Ha HK, Choi BS, Kim KW, Myung SJ, Kim AY, et al. Scirrhous gastric carcinoma: endoscopy versus upper gastrointestinal radiography. Radiology 2004;231:421–426.PubMedCrossRefGoogle Scholar
  11. 11.
    Chen CY, Wu CW, Lo SS, Hsieh MC, Lui WY, Shen KH. Peritoneal carcinomatosis and lymph node metastasis are prognostic indicators in patients with Borrmann type IV gastric carcinoma. Hepatogastroenterology 2002;49:874–877.PubMedGoogle Scholar
  12. 12.
    Japanese Gastric Cancer Association Registration Committee, Maruyama K, Kaminishi M, Hayashi K, Isobe Y, Honda I, et al. Gastric cancer treated in 1991 in Japan: data analysis of nationwide registry. Gastric Cancer 2006;9:51–66.PubMedCrossRefGoogle Scholar
  13. 13.
    Otsuji E, Kuriu Y, Okamoto K, Ochiai T, Ichikawa D, Hagiwara A, et al. Outcome of surgical treatment for patients with scirrhous carcinoma of the stomach. Am J Surg 2004;188:327–332.PubMedCrossRefGoogle Scholar
  14. 14.
    Takahashi I, Matsusaka T, Onohara T, Nishizaki T, Ishikawa T, Tashiro H, et al. Clinicopathological features of long-term survivors of scirrhous gastric cancer. Hepatogastroenterology 2000;47:1485–1488.PubMedGoogle Scholar
  15. 15.
    Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Noguchi Y. Should scirrhous gastric carcinoma be treated surgically? Clinical experiences with 233 cases and a retrospective analysis of prognosticators. Hepatogastroenterology 2001;48:1509–1512.PubMedGoogle Scholar
  16. 16.
    Nakamura R, Saikawa Y, Wada N, Yoshida M, Kubota T, Kumai K, et al. Retrospective analysis of prognosis for scirrhous-type gastric cancer: one institution’s experience. Int J Clin Oncol 2007;12:291–294.PubMedCrossRefGoogle Scholar
  17. 17.
    Aranha GV, Georgen R. Gastric linitis plastica is not a surgical disease. Surgery 1989;106:758–63.PubMedGoogle Scholar
  18. 18.
    Furukawa H, Hiratsuka M, Iwanaga T, Imaoka S, Ishikawa O. Extended surgery — left upper abdominal exenteration plus Appleby’s method — for type 4 gastric carcinoma. Ann Surg Oncol 1997;4:209–214.PubMedCrossRefGoogle Scholar
  19. 19.
    Kobayashi O, Konishi K, Kanari M, Cho H, Yoshikawa T, Tsuburaya A, et al. Unusual survival for more than 2 years with peritoneal metastases of gastric cancer. Gastric Cancer 2002;5:47–50.PubMedCrossRefGoogle Scholar
  20. 20.
    Willett CG. Results of radiation therapy in gastric cancer. Semin Radiat Oncol 2002;12:170–175.PubMedCrossRefGoogle Scholar
  21. 21.
    Furukawa H, Iwanaga T, Hiratsuka M, Imaoka S, Ishikawa O, Kabuto T, et al. Gastric cancer in young adults: growth accelerating effect of pregnancy and delivery. J Surg Oncol 1994;55:3–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Kim JP, Yu HJ, Lee JH. Results of immunochemo-surgery for gastric carcinoma. Hepatogastroenterology 2001;48:1227–1230.PubMedGoogle Scholar
  23. 23.
    Macdonald JS. Adjuvant therapy for gastric cancer. Semin Oncol 2003;30(4 suppl 11):19–25.PubMedCrossRefGoogle Scholar
  24. 24.
    Sindelar WF, Kinsella TJ, Tepper JE, DeLaney TF, Maher MM, Smith R, et al. Randomized trial of intraoperative radiotherapy in carcinoma of the stomach. Am J Surg 1993;165:178–186; discussion 186–187.PubMedCrossRefGoogle Scholar
  25. 25.
    Jeung HC, Moon YW, Rha SY, Yoo NC, Roh JK, Noh SH, et al. Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up. Ann Oncol 2008;19: 520–526.PubMedCrossRefGoogle Scholar
  26. 26.
    Cesana GC, Romano F, Piacentini G, Scotti M, Brenna A, Bovo G, et al. Low-dose interleukin-2 administered pre-operatively to patients with gastric cancer activates peripheral and peritumoral lymphocytes but does not affect prognosis. Ann Surg Oncol 2007;14:1295–304.PubMedCrossRefGoogle Scholar
  27. 27.
    Ueda Y, Fujimura T, Kinami S, Hirono Y, Yamaguchi A, Naitoh H, et al.; Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC). A randomized phase III trial of postoperative adjuvant therapy with S-1 alone versus S-1 plus PSK for stage II/IIIA gastric cancer: Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC). Jpn J Clin Oncol 2006;36:519–522.PubMedCrossRefGoogle Scholar
  28. 28.
    Sakamoto J, Morita S, Kodera Y, Rahman M, Nakao A. Adjuvant chemotherapy for gastric cancer in Japan: global and Japanese perspectives. Cancer Chemother Pharmacol 2004;54suppl 1: S25–S31.PubMedGoogle Scholar
  29. 29.
    Kinoshita T, Konishi M, Nakagohri T, Takahashi S, Gotouda N. Gastric cancer. Jpn J Cancer Chemother 2006;33:313–317.Google Scholar
  30. 30.
    Tanaka F. UFT (tegafur and uracil) as postoperative adjuvant chemotherapy for solid tumors (carcinoma of the lung, stomach, colon/rectum, and breast): clinical evidence, mechanism of action, and future direction. Surg Today 2007;37:923–943.PubMedCrossRefGoogle Scholar
  31. 31.
    Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357: 1810–1820.PubMedCrossRefGoogle Scholar
  32. 32.
    Suga S, Iwase H, Shimada M, Nishio Y, Ichihara T, Ichihara S, et al. Neoadjuvant chemotherapy in scirrhous cancer of the stomach using uracil and tegafur and cisplatin. Intern Med 1996;35:930–936.PubMedCrossRefGoogle Scholar
  33. 33.
    Kinoshita T, Konishi M, Nakagohri T, Inoue K, Oda T, Takahashi S, et al. Neoadjuvant chemotherapy with S-1 for scirrhous gastric cancer: a pilot study. Gastric Cancer 2003;6suppl 1:40–44.PubMedCrossRefGoogle Scholar
  34. 34.
    Takahashi S, Kinoshita T, Konishi M, Nakagouri T, Inoue K, Ono M, et al. Phase II study of sequential high-dose methotrexate and fluorouracil combined with doxorubicin as a neoadjuvant chemotherapy for scirrhous gastric cancer. Gastric Cancer 2001;4:192–197.PubMedCrossRefGoogle Scholar
  35. 35.
    Hippo Y, Yashiro M, Ishii M, Taniguchi H, Tsutsumi S, Hirakawa K, et al. Differential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodes. Cancer Res 2001;61:889–895.PubMedGoogle Scholar
  36. 36.
    Hagiwara A, Takahashi T, Kojima O, Sawai K, Yamaguchi T, Yamane T, et al. Prophylaxis with carbon-absorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet 1992;339:629–631.PubMedCrossRefGoogle Scholar
  37. 37.
    Yu W, Whang I, Suh I, Averbach A, Chang D, Sugarbaker PH. Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 1998;228:347–354.PubMedCrossRefGoogle Scholar
  38. 38.
    Hamazoe R, Maeta M, Kaibara N. Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer 1994;73:2048–2052.PubMedCrossRefGoogle Scholar
  39. 39.
    Ikeguchi M, Kondou A, Oka A, Tsujitani S, Maeta M, Kaibara N. Effect of continuous hyperthermic peritoneal perfusion on prognosis of gastric cancer with serosal invasion. Eur J Surg 1995;161:581–586.PubMedGoogle Scholar
  40. 40.
    Rosen HR, Jatzko G, Repse S, Potrc S, Neudorfer H, Sandbichler P, et al. Adjuvant intraperitoneal chemotherapy with carbonadsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. J Clin Oncol 1998;16:2733–2738.PubMedGoogle Scholar
  41. 41.
    Sautner T, Hofbauer F, Depisch D, Schiessel R, Jakesz R. Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 1994;12:970–974.PubMedGoogle Scholar
  42. 42.
    Topuz E, Basaran M, Saip P, Aydiner A, Argon A, Sakar B, et al. Adjuvant intraperitoneal chemotherapy with cisplatinum, mitoxantrone, 5-fluorouracil, and calcium folinate in patients with gastric cancer: a phase II study. Am J Clin Oncol 2002;25:619–24.PubMedCrossRefGoogle Scholar
  43. 43.
    Shiraishi N, Morimoto A, Sato K, Bandoh T, Adachi Y, Kitano S. Laparoscopy in the management of scirrhous gastric cancer. Gastric Cancer 1999;2:109–114.PubMedCrossRefGoogle Scholar
  44. 44.
    Ikeguchi M, Matsumoto S, Yoshioka S, Murakami D, Kanaji S, Ohro S, et al. Laparoscopic-assisted intraperitoneal chemotherapy for patients with scirrhous gastric cancer. Chemotherapy 2005;51:15–20.PubMedCrossRefGoogle Scholar
  45. 45.
    Ikeguchi M, Kaibara N. Detection of circulating cancer cells after a gastrectomy for gastric cancer. Surg Today 2005;35:436–441.PubMedCrossRefGoogle Scholar
  46. 46.
    Morgan RJ Jr, Doroshow JH, Synold T, Lim D, Shibata S, Margolin K, et al. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Clin Cancer Res 2003;16:5896–901.Google Scholar
  47. 47.
    Shimada T, Nomura M, Yokogawa K, Endo Y, Sasaki T, Miyamoto K, et al. Pharmacokinetic advantage of intraperitoneal injection of docetaxel in the treatment for peritoneal dissemination of cancer in mice. J Pharm Pharmacol 2005;57:177–181.PubMedCrossRefGoogle Scholar
  48. 48.
    Yonemura Y, Bandou E, Sawa T, Yoshimitsu Y, Endou Y, Sasaki T, et al. Neoadjuvant treatment of gastric cancer with peritoneal dissemination. Eur J Surg Oncol 2006;32:661–665.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2009

Authors and Affiliations

  • Masahide Ikeguchi
    • 1
  • Takanori Miyake
    • 1
  • Tomoyuki Matsunaga
    • 1
  • Manabu Yamamoto
    • 1
  • Youji Fukumoto
    • 1
  • Yosinori Yamada
    • 1
  • Kenji Fukuda
    • 1
  • Hiroaki Saito
    • 1
  • Shigeru Tatebe
    • 1
  • Shun-ichi Tsujitani
    • 1
  1. 1.Department of Surgery, Division of Surgical Oncology, Faculty of MedicineTottori UniversityYonagoJapan

Personalised recommendations